Enabling Protein Degradation Drug Discovery

Home » News & Events » News

Horizon & Ubiquigent Enter into Collaboration Agreement

Posted on May 26th, 2016 in News
Horizon's X-MAN® cell lines to be made available in conjunction with Ubiquigent's ubiquitin-related Drug Discovery Services   Cambridge, UK, 26 May 2016: Horizon Discovery Group plc (LSE: HZD) ("Horizon"), the world leader in the application of gene editing technologies including… Read More »

Dundee, UK – the place to access world class ubiquitin system research expertise and capabilities

Posted on May 12th, 2016 in News
Take a look at a great article that was published today in Nature describing how the Division of Signal Transduction Therapy (DSTT) enables pre-competitive access to ubiquitin system research at the University of Dundee. Our friends at the University of… Read More »

Ubiquigent Strengthens Team to Deliver Cutting Edge Drug Discovery Services, Research Tools and Chemistry and Announces Launch of New Website

Posted on February 24th, 2016 in News
Dundee, UK, 24th February, 2016: Ubiquigent Limited, a company specialising in providing ubiquitin cell-signalling system drug discovery services and research tools, announced today that it has significantly enhanced its drug discovery service capabilities by strengthening its commercial and chemistry teams… Read More »

Ubiquigent and Cyclofluidic Enter into Collaboration to Build Novel Ubiquitin System Targeted Compound Libraries

Posted on June 3rd, 2015 in News
Agreement combines ubiquitin focused biology expertise with proprietary chemistry platform to identify small molecule libraries that target the ubiquitin system. Dundee, UK, 3rd June 2015: Ubiquigent Limited, a company specialising in ubiquitin cell-signalling system drug discovery capabilities and services, and… Read More »

Exclusive collaboration with UbiQ to commercialise novel reagents for Parkinson’s Disease research

Posted on April 29th, 2015 in News
Ubiquigent announces an exclusive collaboration with UbiQ to commercialise novel reagents addressing a new frontier of integrated ubiquitylation and phosphorylation research central to Parkinson's Disease Dundee, UK, 29 April 2015: Ubiquigent Limited, a company specialising in providing ubiquitin cell signalling… Read More »

Dr Achim Werner awarded the Ubiquigent Young Scientist Prize

Posted on October 24th, 2014 in News
Dr Achim Werner awarded the Ubiquigent Young Scientist Prize at the EMBO-CONICET meeting on 'Ubiquitin and ubiquitin-like proteins: at the crossroads from chromatin to protein" Dundee, UK, 24th October 2014 - Ubiquigent Ltd. is delighted to announce that Dr Achim Werner was awarded… Read More »

Ubiquigent and University of Dundee announce collaboration to develop novel ubiquitin system targeted compound libraries

Posted on October 8th, 2014 in News
Agreement brings together expertise to design, develop and market small molecule libraries targeting ubiquitin system proteins Dundee, UK, 08th October 2014: Ubiquigent Limited, a company specialising in ubiquitin cell-signalling system drug discovery capabilities and services, and the Drug Discovery Unit (the… Read More »

Ubiquigent announces £0.5m funding and strengthens board of directors with key appointment

Posted on September 18th, 2014 in News
Dundee, UK, 18th Sept 2013: Ubiquigent Limited a company specialising in ubiquitin cell-signalling system drug discovery capabilities and services, today announced it has received £0.5 million in funding from IP Group plc and the Scottish Investment Bank, the investment arm of… Read More »

Ubiquigent Ltd announces the appointment of Cosmo Bio USA Inc as their sole north American product distributor

Posted on January 17th, 2013 in News
Dundee, UK, 17th January 2013 - Ubiquigent Ltd. today announced the appointment of Cosmo Bio USA Inc. as their sole North American Distributor. Commenting on the appointment Ubiquigent's Managing Director Dr Jason Brown said; “Ubiquigent are delighted to be appointing Cosmo Bio… Read More »

Ubiquigent Ltd announces expansion of its DUBprofiler™ service

Posted on November 27th, 2012 in News
Ubiquigent Ltd announces significant expansion of its DUBprofiler™ compound selectivity service enabling the profiling of drug lead compounds versus 35 deubiquitylase enzymes. Dundee, UK, 27th November 2012 - Ubiquigent Ltd. today announced the significant expansion of their DUBprofiler service compound profiling panel from 23… Read More »